Cisplatin Induced Hearing Loss — Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
Citation(s)
A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer